<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03603457</url>
  </required_header>
  <id_info>
    <org_study_id>002</org_study_id>
    <nct_id>NCT03603457</nct_id>
  </id_info>
  <brief_title>OFSEP High Definition Cohort</brief_title>
  <acronym>OFSEP HD</acronym>
  <official_title>OFSEP High Definition Cohort</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EDMUS Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EDMUS Foundation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      For neurologists and patients, it appears that one major unmet need, beside of course a cure&#xD;
      to multiple sclerosis (MS), is to better appreciate the causal factors of disease&#xD;
      progression, and even to obtain reliable predictive tools that could apply on the individual&#xD;
      level and at different key moments in the disease course.&#xD;
&#xD;
      The overarching objective of the OFSEP-HD cohort is to determine prognostic factors of the&#xD;
      evolution of disability in MS in real life, looking at disease characteristics, care&#xD;
      practices potentially modifying the evolution of the disease since MS clinical onset and&#xD;
      along specific post-onset landmarks. This general framework leads to study 3 specific&#xD;
      research objectives:&#xD;
&#xD;
        1. To identify determinants (socio-demographic characteristics, clinical characteristics,&#xD;
           health related quality of life (QoL), changes in classification, and biomarkers) for the&#xD;
           progression of MS disease and its consequences;&#xD;
&#xD;
        2. To study the effectiveness of treatments in real life;&#xD;
&#xD;
        3. To merge both determinants and treatments for creating patient-centered prognostic tools&#xD;
           for identifying specific subgroups of patients and helping making decision to start,&#xD;
           maintain or adapt care management.&#xD;
&#xD;
      To achieve these objectives, the OFSEP (The French multiple sclerosis registry)&#xD;
      infrastructure, managed under a quality insurance system, offers a unique opportunity for the&#xD;
      first time in France to create a large cohort of MS cases, providing high-definition and&#xD;
      sequential multimodal data.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 10, 2018</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Time to reach irreversible Expanded Disability Status Scale (EDSS) scores of 6</measure>
    <time_frame>Through study completion, an average of 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Activity of disease</measure>
    <time_frame>1 year</time_frame>
    <description>Activity is determined, according Lublin 2014, by clinical relapses and/or MRI activity (contrast-enhancing lesions ; new or unequivocally enlarging T2 lesions assessed at least annually)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in T2 lesion load evaluated by analysis of raw MRI</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in quality of life evaluated by EQ-5D-5L scale</measure>
    <time_frame>1 year</time_frame>
    <description>The 5-level EQ-5D version (EQ-5D-5L) consists of the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS).&#xD;
The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The five dimensions can be combined into a number that describes the patient's health state.&#xD;
The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome that reflect the patient's own judgement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in quality of life evaluated by SF-12 scale</measure>
    <time_frame>1 year</time_frame>
    <description>The SF-12 questionnaire uses 12 questions to measure functional health and well-being from the patient's point of view.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in quality of life evaluated by MusiQoL scale</measure>
    <time_frame>1 year</time_frame>
    <description>The MusiQoL (Multiple Sclerosis International Quality of Life Questionnaire) is a multidimensional Health Related Quality of Life instrument that provides information based on the views and perceptions of the participants.</description>
  </primary_outcome>
  <enrollment type="Actual">2900</enrollment>
  <condition>Multiple Sclerosis</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood, serum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All MS patients from MS Clinical Reference Centre (CRC SEP).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of multiple sclerosis according to the most recent criteria at entry into&#xD;
             the HD cohort&#xD;
&#xD;
          -  Followed in one MS Clinical Reference Centre (CRC SEP)&#xD;
&#xD;
          -  Newly diagnosed after the study start or&#xD;
&#xD;
          -  If MS onset occurred before study start, regular follow-up in a CRC SEP&#xD;
&#xD;
          -  Irreversible disability ≤ 7.0 (permanent use of a wheelchair) on EDSS at inclusion in&#xD;
             the study&#xD;
&#xD;
        Non-inclusion Criteria:&#xD;
&#xD;
          -  Inability to answer questionnaires&#xD;
&#xD;
          -  Pregnant women at the time of inclusion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU d'Amiens</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Besançon</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Caen</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Créteil</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Marseille</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nancy</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nîmes</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Pitié-Salpétrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Saint-Antoine</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondation Rothschild</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHI de Poissy-Saint-Germain-en-Laye</name>
      <address>
        <city>Poissy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Fort-de-France</name>
      <address>
        <city>Fort-de-France</city>
        <country>Martinique</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Martinique</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 28, 2018</study_first_submitted>
  <study_first_submitted_qc>July 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2018</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epidemiology</keyword>
  <keyword>Prognostic factors</keyword>
  <keyword>Stratified medicine</keyword>
  <keyword>Quality of life</keyword>
  <keyword>Economic assessment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_url>http://www.ofsep.org/en/data-access</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

